Delivery Order SPE2DB24D3013-SPE2DB25FFKWT

Award Date 4/14/25
Potential Completion Date 4/15/25
Potential Value $14K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML medical devices. The contract has a ceiling value of $10,294.83 and a period of performance through April 8, 2025. It is a firm fixed-price contract and does not have a set-aside designation, indicating open competition. AmerisourceBergen also holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML medical products. The contract has a ceiling value of $9,427.60 and an ultimate completion date of February 21, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4568078146 - ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, a medical product. The contract has a ceiling value of $1,960.14 and a period of performance through April 30, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, a medical product, with a ceiling value of $1,570.91 and a period of performance through March 3, 2025. The contract is a Firm Fixed Price type and does not have any set-aside designation, indicating open competition. AmerisourceBergen holds a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,085.17, is for the provision of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, a medical product. The contract has an ultimate completion date of February 25, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567887736 ! ZEPBOUND 10 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a ceiling value of $4,501.92 and a performance period through April 14, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,836.39, is for the delivery of ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of January 22, 2025. It is not designated as a set-aside award. This delivery order is part of a larger Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML medical supplies. The $1,704.06 firm fixed price contract has an ultimate completion date of February 10, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the supply of ZEPBOUND 12.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with a ceiling value of $5,066.48 and a period of performance through February 19, 2025. The contract is a firm-fixed-price delivery order, without any set-aside designation. AmerisourceBergen holds a significant Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of ZEPBOUND 5 MG/0.5 ML PEN 0.5ML medical supplies. The contract has a ceiling value of $2,287.74 and a period of performance through April 10, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as the primary...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFKWT
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ZEPBOUND 10 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $13,928.91 and runs through April 15, 2025. It is a firm fixed-price contract, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 7/14/25, 11:06 AM